Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.61 |
| ▸ | PTGES | O14684 | 7/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 7/20 | 0.61 |
| ▸ | MMP2 | P08253 | 2/20 | 0.55 |
| ▸ | MMP3 | P08254 | 2/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1856449 | 0.86 | LTA4H (0.60) | PPARGALOX5MMP2MMP3FFAR1 | |
| SCHEMBL22367637 | 0.86 | MMP2 (0.63) | PPARGPTGESALOX5MMP2MMP3 | |
| SCHEMBL29779565 | 0.86 | MMP2 (0.63) | PPARGPTGESALOX5MMP2MMP3 | |
| SCHEMBL7985219 | 0.85 | LMNA (0.54) | PPARGPTGESALOX5FFAR1PPARA | |
| SCHEMBL1856418 | 0.85 | ALDH1A1 (0.56) | ALOX5MMP2MMP3MEN1NPC1 | |
| SCHEMBL8035628 | 0.85 | PPARG (0.48) | PPARGPTGESALOX5MMP2MMP3 | |
| SCHEMBL1131425 | 0.84 | GRIK1 (0.62) | PPARGPTGESALOX5MMP2MMP3 | |
| SCHEMBL473644 | 0.84 | MMP2 (0.61) | PPARGPTGESALOX5MMP2MMP3 | |
| SCHEMBL1857596 | 0.83 | GRIK1 (0.55) | PPARGMMP2MMP3FFAR1PPARA | |
| SCHEMBL1857504 | 0.83 | GRIK1 (0.57) | PPARGPTGESALOX5MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| WO-2009080722-A2 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | AKR1C3, TPD52L2, HCCS | PPARG 3250/4885PTGES 3899/4885ALOX5 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.